엔카타 (NKTX) 주가

엔카타(NKTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.83 (+0.71%), 시가총액 $0.21B, 52주 최저~최고 $1.66 ~ $3.49.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, Ca

핵심 지표

• 현재가: $2.83 (+0.71%)
• 시가총액: $0.21B
• 52주 최저~최고: $1.66 ~ $3.49
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

엔카타의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

엔카타 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.4286

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.67
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문